USA Patient Network

03/08/2026

🌸 Happy International Women’s Day! 🌸

Today, we honor the incredible women advocates who have inspired, led, and fought tirelessly for patient safety, health care access, and the rights of all patients.

At USAPN, we’ve had the privilege of working alongside remarkable women who bring courage, expertise, and compassion to every challenge they take on. Your dedication helps ensure that patients’ voices are heard, valued, and acted upon.

To all the women making a difference in patient advocacy, health care, and beyond — thank you for your leadership, resilience, and vision. Your work moves the needle and makes health care safer and more equitable for everyone.

03/07/2026

🦠 CDC Vaccine Advisory Board Rescheduled Amid Controversy

The CDC’s vaccine advisory committee, a key body guiding nationwide vaccine recommendations, has been rescheduled for March 18–19, 2026 after the February meeting was abruptly canceled.

This disruption comes amid major changes at the agency under Health Secretary Robert F. Kennedy Jr., including the unexpected dismissal of the previous committee, raising alarms in the medical and scientific community. Experts are expressing concern about scientific rigor, independence, and impartiality in decision-making.

For patients, families, and public health advocates, this is more than bureaucracy — it affects trust, access, and confidence in vaccines that protect millions of Americans. Decisions made by this advisory board can shape policies on vaccine safety, distribution, and recommendations across the country.

We’re watching closely and will continue to advocate for transparent, evidence-based public health decisions that put patients first.



https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-vaccine-panel-meet-march-18-2026-02-24/?utm_source=chatgpt.com

03/06/2026

The nominee for Surgeon General, Casey Means, still doesn’t have the votes for confirmation, and for good reason. Recent hearings raised serious concerns about whether she would provide the decisive leadership Americans need in public health.

Statements about “real food,” “root causes,” and “shared decision-making” may sound appealing — but words alone do not change the fact that millions of Americans face systemic barriers to health. Without addressing access, affordability, and equity, these become empty slogans.

Equally concerning is the handling of vaccines. The Surgeon General’s role is to make population-level public health recommendations, yet repeated deflections to “talk to your doctor” show a lack of willingness to lead with clarity and authority.

Patients, families, and health care workers deserve a Surgeon General who acts with substance, not soundbites. Leadership in this role should mean guiding policy, promoting real solutions, and protecting public health — not just offering well-phrased talking points.



https://www.politico.com/news/2026/02/26/surgeon-general-casey-means-vaccines-nomination-rfk-00801331

03/05/2026

📣 Self‑Advocacy in Healthcare Matters — Especially for Autistic Adults

Navigating medical appointments and hospital stays can be overwhelming for anyone — and yet many autistic adults face added challenges that turn routine care into stressful, sometimes traumatic experiences.

A new resource from the Autistic Self Advocacy Network offers clear, practical tools to help autistic adults communicate their needs in medical settings and reduce overwhelm. These tips aren’t about “fixing” neurodivergent people — they’re about equipping them with strategies so medical care can work with how their brain and senses operate, not against them.

Some of the key tools and strategies include:
🧠 Preparing ahead of time — writing down questions, preferences, and sensory needs before appointments
🗣️ Using communication supports — such as text communication, written notes, or assistive devices
🔄 Explaining sensory needs clearly — e.g., sensitivities to touch, sound, lighting, etc.
🤝 Asking for reasonable adjustments — such as extra time, quiet waiting areas, or clear step‑by‑step explanations

Good healthcare isn’t just about medicine — it’s about understanding the person receiving care. Everyone deserves a medical experience that respects how they process information, communicate, and feel comfortable.

If you or someone you care for is autistic, this is a valuable guide to help make medical interactions less overwhelming and more empowering.

Read more here:
👉 https://autisticadvocacy.org/2026/02/self-advocacy-for-autistic-adults-in-medical-settings-practical-tools-that-reduce-overwhelm/

03/04/2026

State legislatures across the country are advancing bills that would finally allow qualified medical ma*****na patients to use their medicine while hospitalized or in care facilities — something that currently isn’t guaranteed even where medical cannabis is legal. These proposals are often known as “Ryan’s Law”-style reforms, and at least a dozen states are exploring them this year.

Right now, many patients who rely on medical ma*****na for serious symptoms lose access to their medicine the moment they enter a hospital because hospitals don’t allow cannabis on their premises. That can mean going without a medication that has been critical for managing pain, nausea, anxiety or other conditions simply because of where they are — even if it’s legal in their state.

One real example comes from the story that inspired the original “Ryan’s Law” — a cancer patient whose pain was so severe in the hospital that doctors treated it with heavy opioids that left him too sedated to interact with his family. When he was moved to a facility that allowed medical cannabis, he was better able to stay alert and present with loved ones during his final days. (That experience has shaped how reformers view compassionate care.)

Bills like these would:
• Give qualifying patients the legal right to use medical cannabis in hospitals, hospices and long-term care facilities
• Require health care facilities to establish safe policies for storing and handling a patient’s medicine
• Protect patients from being forced to stop a treatment that doctors and patients have already determined benefits them

This isn’t just policy talk — it’s about dignity, continuity of care, and preventing needless suffering for patients who already face difficult health battles.

Patients shouldn’t have to choose between the hospital care they need and the medicine that helps them through it.



https://www.ma*****namoment.net/bills-to-let-patients-use-medical-ma*****na-in-hospitals-are-advancing-in-states-across-the-u-s/

03/03/2026

Health care reform may become a major talking point heading into the midterms — but actually passing meaningful legislation will be an uphill battle.

Lowering costs is politically popular. Voters across the spectrum are feeling the strain of:

• Rising insurance premiums
• High deductibles
• Prescription drug prices
• Unpredictable out-of-pocket costs

President Donald Trump has sent mixed signals about whether health reform is a priority. Some affordability goals — like promoting healthier lifestyles — can move forward administratively. But most efforts to lower drug prices or insurance costs would require Congress to act.

And that’s where things get complicated.

Key challenges include:

🔹 Major legislation vehicles have already been used
🔹 Narrow margins in Congress make sweeping reform unlikely
🔹 Disagreements over drug pricing policies
🔹 Debate over expanding Health Savings Accounts (HSAs)
🔹 Ongoing negotiations around FDA user fee programs

There is also growing discussion about potential reforms to Medicare Advantage and changes to the way the Food and Drug Administration is funded and structured.

The reality?
Lawmakers will likely talk a lot about health care affordability this year — but delivering real cost relief to patients may prove far more difficult.

At USAPN, we believe affordability must mean:

✔️ Transparent pricing
✔️ Evidence-based policy
✔️ Protection of public health safeguards
✔️ Solutions that put patients — not politics — first

Health care shouldn’t just be a campaign issue. It should be a commitment.

03/02/2026

Pharma’s New Target: The FDA

Food and Drug Administration has historically been insulated from political pressure so that drug approvals are based on science — not influence.

But according to recent reporting, that firewall may be weakening under Donald Trump’s administration.

Pharmaceutical companies are reportedly shifting their lobbying strategies — going beyond traditional regulatory engagement and appealing directly to the White House and senior health officials when FDA decisions don’t go their way.

Recent reporting highlights:

Companies reaching out to the White House after unfavorable FDA decisions

Reversals of agency positions following political engagement

Increased congressional inquiries into specific drug applications

A surge in pharma lobbying spending — reportedly the largest single-year increase on record

Health Secretary Robert F. Kennedy Jr. has publicly pledged to root out industry influence. Meanwhile, FDA Commissioner Marty Makary has defended the agency’s scientific integrity.

But the core issue remains:

If drug approvals — or reversals — appear tied to political relationships or policy deals, public trust erodes.

Patients deserve confidence that:
✔️ Drugs are approved based on rigorous evidence
✔️ Regulatory decisions are insulated from political bargaining
✔️ Scientific review cannot be fast-tracked through influence

The FDA is one of the most important public health institutions in the world. Its credibility depends on independence.

At USAPN, we believe patient safety must always come before politics, industry pressure, or deal-making.

Because when regulatory integrity weakens, patients bear the risk.

03/01/2026

🧬 FDA Denies Expedited Approval for Rare Disease Drug Bitopertin

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Disc Medicine for its investigational drug bitopertin, which was being studied to treat erythropoietic protoporphyria (EPP) — a rare genetic disorder that causes severe, painful sensitivity to sunlight.

Bitopertin had been under review through an accelerated approval pathway, one of the FDA’s programs designed to bring promising treatments to patients faster. However, the agency determined that while the drug lowered a key disease biomarker, there was not yet enough evidence showing clear, meaningful improvement in patients’ daily lives — such as increased pain-free sunlight exposure.

🔎 What this means for patients:
The company will now continue its Phase 3 clinical trial (APOLLO) and pursue a traditional FDA approval pathway based on more comprehensive data.

⚖️ Why this matters:
Expedited programs are important tools to speed innovation — especially for rare diseases — but this decision underscores the FDA’s requirement that accelerated approvals still demonstrate real clinical benefit for patients.

USA Patient Network will continue monitoring developments and advocating for transparency, strong evidence standards, and patient safety.



https://www.reuters.com/business/healthcare-pharmaceuticals/disc-medicine-pursue-traditional-us-approval-after-fda-rejects-new-fast-track-2026-02-17/?utm_source=chatgpt.com

02/28/2026

📣 URGENT: Why Paying FDA Reviewers Bonuses for Speed Is Dangerous for Patients

The FDA’s plan to pay bonuses to drug reviewers for speeding up drug approvals isn’t a “quality improvement” — it’s a dangerous shortcut that risks patient safety and undermines trust in the regulatory system. 

Here’s why this idea is unethical and harmful:

🚨 Creates a Financial Incentive to Rush Reviews
Giving reviewers cash bonuses for finishing faster directly links their paycheck to speed, not safety. Drug review is a scientific process — not a race — and shortcuts can mean unsafe drugs reach the market. 

📉 Risk of Lowering Safety Standards
Even the FDA’s own documents highlight ethical concerns that speeding up reviews could push reviewers to “rush steps needed to confirm drug safety and effectiveness.” 

👩‍⚕️ Erodes Public Trust
The FDA exists to protect patients. When reviewers are rewarded for speed, it fuels public fear that approval decisions may prioritize incentives over thorough science. That undermines confidence in every medical product that comes through the agency.

⚖️ Potential Bias Toward Industry Interests
About 70% of FDA drug program funding already comes from industry user fees. Adding bonus pay tied to faster reviews deepens the perception — and the risk — that the agency is influenced more by industry goals than by patient safety. 

📢 Bottom Line:
Patient safety should never be up for sale. Rewards tied to speed instead of science jeopardize the protections Americans count on when taking medications. We must keep the FDA accountable to sound science, not incentives to cut corners.

Welcome to another installment of This Week at FDA, your weekly source for updates@big and small@on FDA, drug, and medical device regulation and what we@re reading from around the web. This week, FDA reportedly offered drug reviewers bonuses to speed regulatory decisions, the FDA commissioner defend...

02/28/2026

🚨 Patient Safety Alert: Johnson & Johnson Cerepak Coils 🚨

If you are scheduled for a procedure to treat a brain aneurysm, and your doctor plans to use a Cerepak detachable coil, it’s important to talk to your healthcare provider first.

These coils have been recalled because they may fail to detach properly during the procedure, which can lead to serious complications such as stroke, additional surgery, or other injuries.

✅ What to do:

Ask your doctor if the Cerepak coil would be used in your procedure.
Discuss alternative options or precautions your doctor can take.
Make sure your healthcare team is aware of the recall.

⚠️ Tip: If you’ve already had a procedure and experienced no complications, there’s no ongoing risk — the concern is only during the procedure itself.

https://www.medtechdive.com/news/JNJ-recalls-Cerepak-coil-systems-aneurysm-treatment/811585/

02/28/2026

February 2026 Newsletter - https://mailchi.mp/bb57e895102a/feb_2026_newsletter

02/27/2026

🧪 Scientists Urge Caution About an Ingredient in Oral Weight‑Loss Pills

Researchers are raising important questions about salcaprozate sodium (SNAC) — the ingredient used in oral versions of semaglutide (the active drug in Ozempic and other weight‑loss/diabetes treatments) to help the medication get absorbed into the bloodstream.

📌 Key findings from early animal research:
• SNAC exposure was linked to changes in the gut microbiome, including fewer beneficial bacteria that help break down fiber.
• Levels of short‑chain fatty acids — important for gut lining health and inflammation control — were lower.
• Inflammatory markers in the blood were higher, and liver size increased in ways consistent with low‑grade inflammation.
• Some changes extended beyond the gut, suggesting SNAC might affect other biological systems.

👉 Importantly, this doesn’t prove harm in people — the findings come from animal studies — but they raise questions about long‑term, daily exposure to SNAC as these pills become more widely used.

As oral weight‑loss medications grow in popularity because they are more convenient and potentially less expensive than injections, scientists say it’s critical to understand all components in these therapies — not just the main drug — to ensure safety over the long term.